FOLFOX6/FOLFIRI plus Sorafenib in second-line Colorectal cancer (FOSCO)
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2523967
下载链接
链接失效反馈官方服务：
资源简介：
Primary objectives: To compare the PFS between patients receiving chemotherapy(FOLFOX6 or FOLFIRI) + sorafenib with chemotherapy + placebo
Primary endpoints: The primary efficacy variable is progression-free survival (PFS) and will be analyzed afterat least 186 events (i.e. disease progressions) have occurred.
创建时间：
2009-02-15
